Early-phase treatment by low-dose 5-fluorouracil or primary tumor resection inhibits MDSC-mediated lung metastasis formation

Anticancer Research

Volumn 35, Issue 8, 2015, Pages 4425-4432

  Otsubo, Dai ^a   Yamashita, Kimihiro ^a   Fujita, Mitsugu ^b   Nishi, Masayasu ^a   Kimura, Yutaka ^a   Hasegawa, Hiroshi ^a   Suzuki, Satoshi ^a   Kakeji, Yoshihiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kindai University   (Japan)

Author keywords

5 FU; Lung metastasis; MDSC; Primary resection; Tumor immunity

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL SUSPENSION; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; LOW DRUG DOSE; LUNG METASTASIS; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN CELL; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW CELL; C57BL MOUSE; DRUG EFFECTS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; PATHOLOGY; SECONDARY; SECONDARY PREVENTION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; FLUOROURACIL; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYELOID CELLS; SECONDARY PREVENTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84939815920     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Nguyen DX, Bos PD and Massague J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
2. Vesely MD, Kershaw MH, Schreiber RD and Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271, 2011.
3. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162- 174, 2009.
4. Kadowaki T, Shimada M, Inagawa H, Kohchi C, Hirashima M and Soma G: Reconsideration of macrophage and dendritic cell classification. Anticancer Res 32: 2257-2261, 2012.
5. Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499- 506, 2009.
6. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253-268, 2012.
7. Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713-6721, 2005.
8. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K and de Gruijl TD: Sunitinibinduced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progressionfree survival. Clin Cancer Res 14: 5884-5892, 2008.
9. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S and Djeu JY: A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16: 4583-4594, 2010.
10. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C and Ghiringhelli F: 5- Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70: 3052-3061, 2010.
11. Zitvogel L, Apetoh L, Ghiringhelli F and Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73, 2008.
12. Hasegawa H, Yamashita K, Otubo D, Fujii S, Kamigaki T, Kuroda D and Kakeji Y: Allogeneic DCG promote lung NK cell activation and antitumor effect after invariant NKT cell activation. Anticancer Res 34: 3411-3417, 2014.
13. Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K and Kakimi K: Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloidderived suppressor cells. Int J Cancer 134: 1810-1822, 2014.
14. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J and Illidge TM: Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74: 5458-5468, 2014.
15. Athawale RB, Jain DS, Singh KK and Gude RP: Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed Pharmacother 68: 231-240, 2014.
16. Yasuda Y, Fujita M, Koike E, Obata K, Shiota M, Kotani Y, Musha T, Tsuji-Kawahara S, Sato T, Masuda S, Okano J, Yamasaki H, Okumoto K, Uesugi T, Nakao S, Hoshiai H and and Mandai M: Erythropoietin receptor antagonist suppressed ectopic hemoglobin synthesis in xenografts of HeLa cells to promote their destruction. PLoS One 10: E0122458, 2015.
17. Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802, 2008.
18. Schilsky RL: Biochemical and clinical pharmacology of 5- fluorouracil. Oncology (Williston Park) 12: 13-18, 1998.
19. Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD and Takabe K: Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 153: 771-778, 2013.